Avid Bioservices, Inc. (CDMO): Price and Financial Metrics


Avid Bioservices, Inc. (CDMO): $13.01

-1.87 (-12.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CDMO POWR Grades

  • CDMO scores best on the Sentiment dimension, with a Sentiment rank ahead of 38.96% of US stocks.
  • The strongest trend for CDMO is in Stability, which has been heading down over the past 177 days.
  • CDMO ranks lowest in Growth; there it ranks in the 3rd percentile.

CDMO Stock Summary

  • The price/operating cash flow metric for AVID BIOSERVICES INC is higher than 95.51% of stocks in our set with a positive cash flow.
  • Of note is the ratio of AVID BIOSERVICES INC's sales and general administrative expense to its total operating expenses; 86.89% of US stocks have a lower such ratio.
  • For CDMO, its debt to operating expenses ratio is greater than that reported by 88.92% of US equities we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AVID BIOSERVICES INC are CBZ, TRC, TIRX, SXTC, and JUPW.
  • CDMO's SEC filings can be seen here. And to visit AVID BIOSERVICES INC's official web site, go to avidbio.com.

CDMO Valuation Summary

  • In comparison to the median Healthcare stock, CDMO's price/sales ratio is 305% higher, now standing at 8.1.
  • Over the past 243 months, CDMO's price/earnings ratio has gone up 14.

Below are key valuation metrics over time for CDMO.

Stock Date P/S P/B P/E EV/EBIT
CDMO 2022-12-02 8.1 5.7 8.3 97.7
CDMO 2022-12-01 7.8 5.5 8.0 94.2
CDMO 2022-11-30 7.8 5.4 7.9 93.5
CDMO 2022-11-29 7.3 5.1 7.4 88.3
CDMO 2022-11-28 7.4 5.2 7.6 89.8
CDMO 2022-11-25 7.3 5.1 7.4 88.2

CDMO Growth Metrics

    The year over year revenue growth rate now stands at 24.75%.
  • Its 3 year cash and equivalents growth rate is now at 277.65%.
  • Its 2 year cash and equivalents growth rate is now at 245.56%.
Over the past 15 months, CDMO's revenue has gone up $29,667,000.

The table below shows CDMO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 125.535 11.373 122.932
2022-03-31 119.597 9.465 127.672
2021-12-31 115.977 26.713 9.775
2021-09-30 106.275 26.71 8.292
2021-06-30 101.23 26.513 5.612
2021-03-31 95.868 31.182 3.318

CDMO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CDMO has a Quality Grade of C, ranking ahead of 27.37% of graded US stocks.
  • CDMO's asset turnover comes in at 0.495 -- ranking 83rd of 682 Pharmaceutical Products stocks.
  • COCP, HROW, and IBIO are the stocks whose asset turnover ratios are most correlated with CDMO.

The table below shows CDMO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-31 0.495 0.318 0.126
2021-04-30 0.587 0.306 0.157
2021-01-31 0.653 0.246 0.079
2020-10-31 0.672 0.199 0.002
2020-07-31 0.659 0.163 -0.044
2020-04-30 0.568 0.066 -0.173

CDMO Price Target

For more insight on analysts targets of CDMO, see our CDMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $28.25 Average Broker Recommendation 1.38 (Strong Buy)

CDMO Stock Price Chart Interactive Chart >

Price chart for CDMO

CDMO Price/Volume Stats

Current price $13.01 52-week high $31.01
Prev. close $14.88 52-week low $11.30
Day low $11.34 Volume 1,137,379
Day high $13.30 Avg. volume 617,064
50-day MA $16.07 Dividend yield N/A
200-day MA $16.87 Market Cap 808.79M

Avid Bioservices, Inc. (CDMO) Company Bio


Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, researches and develops monoclonal antibodies for the treatment of cancer in the United States. Its lead immunotherapy candidate includes bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company was founded in 1981 and is based in Tustin, California.


CDMO Latest News Stream


Event/Time News Detail
Loading, please wait...

CDMO Latest Social Stream


Loading social stream, please wait...

View Full CDMO Social Stream

Latest CDMO News From Around the Web

Below are the latest news stories about AVID BIOSERVICES INC that investors may wish to consider to help them evaluate CDMO as an investment opportunity.

Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2023 After Market Close on December 6, 2022

TUSTIN, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the second quarter of fiscal year 2023 on December 6, 2022 after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members

Yahoo | November 29, 2022

Avid Bioservices (NASDAQ:CDMO) jumps 12% this week, though earnings growth is still tracking behind five-year shareholder returns

Avid Bioservices, Inc. ( NASDAQ:CDMO ) shareholders might be concerned after seeing the share price drop 23% in the...

Yahoo | November 17, 2022

Avid Bioservices Appoints Oksana Lukash as Vice President, People

TUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial org

Yahoo | November 16, 2022

Avid Bioservices to Participate in the Credit Suisse 31st Annual Healthcare Conference

TUSTIN, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the Credit Suisse 31st Annual Healthcare Conference. Nick Green, president and chief executive officer of Avid Bioservices, will deli

Yahoo | November 2, 2022

Does Avid Bioservices (CDMO) Have the Potential to Rally 61% as Wall Street Analysts Expect?

The consensus price target hints at a 60.5% upside potential for Avid Bioservices (CDMO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | October 17, 2022

Read More 'CDMO' Stories Here

CDMO Price Returns

1-mo -1.81%
3-mo -24.45%
6-mo 2.68%
1-year -54.35%
3-year 124.70%
5-year 147.34%
YTD -55.41%
2021 152.86%
2020 50.46%
2019 87.07%
2018 5.67%
2017 78.80%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9441 seconds.